BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 19326175)

  • 1. Time sensitivity: a parameter reflecting tumor metabolic kinetics by variable dual-time F-18 FDG PET imaging.
    Wong CY; Noujaim D; Fu HF; Huang WS; Cheng CY; Thie J; Dalal I; Chang CY; Nagle C
    Mol Imaging Biol; 2009; 11(4):283-90. PubMed ID: 19326175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
    Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value.
    Higgins KA; Hoang JK; Roach MC; Chino J; Yoo DS; Turkington TG; Brizel DM
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):548-53. PubMed ID: 21277108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter Clinical Trials Using 18F-FDG PET to Measure Early Response to Oncologic Therapy: Effects of Injection-to-Acquisition Time Variability on Required Sample Size.
    Kurland BF; Muzi M; Peterson LM; Doot RK; Wangerin KA; Mankoff DA; Linden HM; Kinahan PE
    J Nucl Med; 2016 Feb; 57(2):226-30. PubMed ID: 26493206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there a correlation between 18F-FDG-PET standardized uptake value, T-classification, histological grading and the anatomic subsites in newly diagnosed squamous cell carcinoma of the head and neck?
    Haerle SK; Huber GF; Hany TF; Ahmad N; Schmid DT
    Eur Arch Otorhinolaryngol; 2010 Oct; 267(10):1635-40. PubMed ID: 20680640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normal FDG distribution patterns in the head and neck: PET/CT evaluation.
    Nakamoto Y; Tatsumi M; Hammoud D; Cohade C; Osman MM; Wahl RL
    Radiology; 2005 Mar; 234(3):879-85. PubMed ID: 15734938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor to cervical spinal cord standardized uptake ratio (SUR) improves the reproducibility of
    van den Bosch S; Dijkema T; Philippens MEP; Terhaard CHJ; Hoebers FJP; Kaanders JHAM; Oyen WJG
    Radiother Oncol; 2019 Jan; 130():39-45. PubMed ID: 30005954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Test-Retest Variability in Lesion SUV and Lesion SUR in
    Hofheinz F; Apostolova I; Oehme L; Kotzerke J; van den Hoff J
    J Nucl Med; 2017 Nov; 58(11):1770-1775. PubMed ID: 28473598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preliminary assessment of dynamic contrast-enhanced CT implementation in pretreatment FDG-PET/CT for outcome prediction in head and neck tumors.
    Abramyuk A; Wolf G; Shakirin G; Haberland U; Tokalov S; Koch A; Appold S; Zöphel K; Abolmaali N
    Acta Radiol; 2010 Sep; 51(7):793-9. PubMed ID: 20583948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG.
    Hustinx R; Lemaire C; Jerusalem G; Moreau P; Cataldo D; Duysinx B; Aerts J; Fassotte MF; Foidart J; Luxen A
    J Nucl Med; 2003 Apr; 44(4):533-9. PubMed ID: 12679396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of dual-time-point 18F-FDG PET-CT imaging in patients with head and neck squamous cell carcinoma.
    Abgral R; Le Roux PY; Rousset J; Querellou S; Valette G; Nowak E; Turzo A; Tissot V; Marianowski R; Salaün PY
    Nucl Med Commun; 2013 Jun; 34(6):551-6. PubMed ID: 23587836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interobserver variability among measurements of the maximum and mean standardized uptake values on (18)F-FDG PET/CT and measurements of tumor size on diagnostic CT in patients with pulmonary tumors.
    Huang YE; Chen CF; Huang YJ; Konda SD; Appelbaum DE; Pu Y
    Acta Radiol; 2010 Sep; 51(7):782-8. PubMed ID: 20707663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDG-PET staging and importance of lymph node SUV in head and neck cancer.
    Kubicek GJ; Champ C; Fogh S; Wang F; Reddy E; Intenzo C; Dusing RW; Machtay M
    Head Neck Oncol; 2010 Jul; 2():19. PubMed ID: 20637102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of whole-body FDG-PET in preoperative assessment of tumor staging in oral cancers.
    Nakasone Y; Inoue T; Oriuchi N; Takeuchi K; Negishi A; Endo K; Mogi K
    Ann Nucl Med; 2001 Dec; 15(6):505-12. PubMed ID: 11831398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Differentiation of malignant and benign superficial lymph nodes by dual time point 18F-FDG PET].
    Su MG; Fan QP; Tian Y; Li FL; Yang XC; Li L; Fan CZ; Tian R
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 May; 40(3):517-20. PubMed ID: 19627018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic evaluation of malignant head and neck cancer by F-18-FDG PET compared to CT/MRI.
    Nowak B; Di Martino E; Jänicke S; Cremerius U; Adam G; Zimny M; Reinartz P; Büll U
    Nuklearmedizin; 1999; 38(8):312-8. PubMed ID: 10615664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of 18F-FDG PET/CT as a predictive biomarker of outcome in patients with head-and-neck non-squamous cell carcinoma.
    Imsande HM; Davison JM; Truong MT; Devaiah AK; Mercier GA; Ozonoff AJ; Subramaniam RM
    AJR Am J Roentgenol; 2011 Oct; 197(4):976-80. PubMed ID: 21940588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT.
    Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E; Ebied O
    Eur J Radiol; 2009 Jun; 70(3):530-8. PubMed ID: 18395387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
    Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
    Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.